These findings necessitate further research to elucidate TRAIL-DR5 regulatory mechanisms in viral hepatitis, distinguish between the expression levels in virus-infected versus normal cells, and ensure the safety and efficacy of both DR5 antagonists and agonists. This evidence concerns the gene TNFRSF10B and viral hepatitis.